Ahmad Nafees, Javaid Arshad, Sulaiman Syed Azhar Syed, Ming Long Chiau, Ahmad Izaz, Khan Amer Hayat
Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Department of Pulmonology, Postgraduate Medical Institute, Peshawar, Pakistan.
Braz J Infect Dis. 2016 Jan-Feb;20(1):41-7. doi: 10.1016/j.bjid.2015.09.011. Epub 2015 Nov 25.
Fluoroquinolones are the backbone of multidrug resistant tuberculosis treatment regimens. Despite the high burden of multidrug resistant tuberculosis in the country, little is known about drug resistance patterns, prevalence, and predictors of fluoroquinolones resistance among multidrug resistant tuberculosis patients from Pakistan.
To evaluate drug resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients.
This was a cross-sectional study conducted at a programmatic management unit of drug resistant tuberculosis, Lady Reading Hospital Peshawar, Pakistan. Two hundred and forty-three newly diagnosed multidrug resistant tuberculosis patients consecutively enrolled for treatment at study site from January 1, 2012 to July 28, 2013 were included in the study. A standardized data collection form was used to collect patients' socio-demographic, microbiological, and clinical data. SPSS 16 was used for data analysis.
High degree of drug resistance (median 5 drugs, range 2-8) was observed. High proportion of patients was resistant to all five first-line anti-tuberculosis drugs (62.6%), and more than half were resistant to second line drugs (55.1%). The majority of the patients were ofloxacin resistant (52.7%). Upon multivariate analysis previous tuberculosis treatment at private (OR=1.953, p=0.034) and public private mix (OR=2.824, p=0.046) sectors were predictors of ofloxacin resistance.
The high degree of drug resistance observed, particularly to fluoroquinolones, is alarming. We recommend the adoption of more restrictive policies to control non-prescription sale of fluoroquinolones, its rational use by physicians, and training doctors in both private and public-private mix sectors to prevent further increase in fluoroquinolones resistant Mycobacterium tuberculosis strains.
氟喹诺酮类药物是耐多药结核病治疗方案的核心。尽管该国耐多药结核病负担沉重,但对于来自巴基斯坦的耐多药结核病患者中氟喹诺酮类药物的耐药模式、患病率及耐药预测因素知之甚少。
评估耐多药结核病患者中氟喹诺酮类药物的耐药模式、患病率及耐药预测因素。
这是一项在巴基斯坦白沙瓦市雷丁夫人医院耐药结核病规划管理单位开展的横断面研究。纳入了2012年1月1日至2013年7月28日在研究地点连续登记接受治疗的243例新诊断耐多药结核病患者。使用标准化数据收集表收集患者的社会人口学、微生物学及临床数据。采用SPSS 16进行数据分析。
观察到高度耐药(中位数为5种药物,范围为2 - 8种)。高比例患者对所有五种一线抗结核药物耐药(62.6%),超过半数患者对二线药物耐药(55.1%)。大多数患者对氧氟沙星耐药(52.7%)。多因素分析显示,既往在私立(OR = 1.953,p = 0.034)和公私混合部门(OR = 2.824,p = 0.046)接受过结核病治疗是氧氟沙星耐药的预测因素。
观察到的高度耐药情况,尤其是对氟喹诺酮类药物的耐药,令人担忧。我们建议采取更严格的政策来控制氟喹诺酮类药物的非处方销售,医生合理使用该药物,并对私立及公私混合部门的医生进行培训,以防止耐氟喹诺酮类结核分枝杆菌菌株进一步增加。